Adimanebart IV

Pipeline

Status by Indication[2][1]

Competition

Competitive Landscape

4 competitors in Congenital Myasthenic Syndrome

#DrugCompanyPhaseTrials

1

Ephedrine Sulfate

DDr. Reddys Laboratories, SA

Approved

—2

Adimanebart IV

Argenx

Phase 3

13

Alloex

TThe Foundation for Orthopaedics and Regenerative Medicine

Phase 1

14

ARGX-119

Argenx

Phase 1

15

Firdapse

CCatalyst Pharmaceuticals, Inc.

Preclinical

1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Congenital Myasthenic Syndrome1 trial

Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study With an Open-Label Extension to Evaluate the Efficacy and Safety of Intravenous Adimanebart in Adult and Pediatric Participants With DOK7-,MUSK-, AGRN-, or LRP4-CMS

Not yet recruiting·Argenx·Phase 3·NCT07746089·105 enrolled

Unspecified1 trial

A Phase 1, Open-Label, Randomized, Single Dose, Parallel-Group Study to Assess the Absolute Bioavailability and Evaluate the Effect of Body Weight on the Pharmacokinetics of Adimanebart SC in Healthy Adult Participants

Recruiting·Argenx·Phase 1·NCT07673601·52 enrolled

Details

Drug Info

Related News